- Home
- RFMZ vs HRTX Comparison
RFMZ vs HRTX Comparison
Compare RFMZ & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFMZ
- HRTX
- Stock Information
- Founded
- RFMZ 2021
- HRTX 1983
- Country
- RFMZ United States
- HRTX United States
- Employees
- RFMZ N/A
- HRTX 122
- Industry
- RFMZ Trusts Except Educational Religious and Charitable
- HRTX Biotechnology: Pharmaceutical Preparations
- Sector
- RFMZ Finance
- HRTX Health Care
- Exchange
- RFMZ Nasdaq
- HRTX Nasdaq
- Market Cap
- RFMZ 310.1M
- HRTX 206.9M
- IPO Year
- RFMZ N/A
- HRTX 1987
- Fundamental
- Price
- RFMZ $12.54
- HRTX $1.35
- Analyst Decision
- RFMZ
- HRTX Strong Buy
- Analyst Count
- RFMZ 0
- HRTX 2
- Target Price
- RFMZ N/A
- HRTX $4.50
- AVG Volume (30 Days)
- RFMZ 76.6K
- HRTX 2.6M
- Earning Date
- RFMZ 01-01-0001
- HRTX 08-08-2025
- Dividend Yield
- RFMZ 7.43%
- HRTX N/A
- EPS Growth
- RFMZ N/A
- HRTX N/A
- EPS
- RFMZ 0.65
- HRTX N/A
- Revenue
- RFMZ N/A
- HRTX $149,694,000.00
- Revenue This Year
- RFMZ N/A
- HRTX $10.62
- Revenue Next Year
- RFMZ N/A
- HRTX $12.99
- P/E Ratio
- RFMZ $21.49
- HRTX N/A
- Revenue Growth
- RFMZ N/A
- HRTX 9.78
- 52 Week Low
- RFMZ $11.28
- HRTX $1.04
- 52 Week High
- RFMZ $14.57
- HRTX $2.68
- Technical
- Relative Strength Index (RSI)
- RFMZ 44.54
- HRTX 36.48
- Support Level
- RFMZ $12.45
- HRTX $1.33
- Resistance Level
- RFMZ $12.61
- HRTX $1.43
- Average True Range (ATR)
- RFMZ 0.13
- HRTX 0.07
- MACD
- RFMZ -0.02
- HRTX 0.02
- Stochastic Oscillator
- RFMZ 13.24
- HRTX 45.45
About RFMZ RiverNorth Flexible Municipal Income Fund II Inc.
RiverNorth Flex Muni Income Fund II Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.